Sign up Australia
Proactive Investors - Run By Investors For Investors

Patrys' positive pre-clinical data puts it on the podium of ASX Top % Gainers

Patrys has traded over 27 million shares in the first hour of the session.
Patrys' positive pre-clinical data puts it on the podium of ASX Top % Gainers
The leading ASX % gainers in morning trade

Patrys Ltd's (ASX:PAB) shares are up 75% in morning trade at $0.007, following positive pre-clinical data for its lead drug candidate PAT-DX1, a novel first-in-class drug candidate being developed to treat a range of different cancers.

Studies in multiple pre-clinical models of cancer have demonstrated the ability of Patrys’ proprietary humanized antibody, PAT-DX1 to be taken-up and to kill cancer cells.

This confirms the successful humanization and de-immunization of 3E10-derived antibody fragments with conserved structural properties and enhanced in vitro activity.

Company Name Code Last Change Volume
Maximus Resources Ltd MXR $0.002 100% 653,760
Patrys Ltd PAB $0.007 75% 27,240,497
Emperor Range Group Ltd ERX $0.060 71.43% 8,400
Bass Oil Ltd BAS $0.003 50% 1,200,000
Pancontinental Oil & Gas NL PCL $0.004 33.33% 148,097,873
Shareroot Ltd SRO $0.009 28.57% 10,354,000
Strandline Resources Ltd STA $0.005 25% 400,000
UUV Aquabotix Ltd UUV $0.120 25% 269,478
Chapmans Ltd CHP $0.005 25% 650,000
NTM Gold Ltd NTM $0.055 22.22% 33,800

 

View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

Cello
April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006
mobile phone
January 22 2018
Tremor is already in profit a year ahead of expectations and is a blueprint for similar acquisitions in the future.
Clint Eastwood
May 25 2018
The group’s first piece of original content, a documentary called Pandas, premiered on 24 March this year, to positive reviews.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use